Preliminary
A new journal. IJRM-SSS is being established and has not yet published its first issue. The editorial board, article records, DOIs, ISSN and indexing status shown here are placeholders — no article listed has been peer reviewed or published.
An official journal of SIRiiM →
IJRM-SSS · The Orange Journal
International Journal of
Radiation Medicine
Screening  ·  Surveillance  ·  Survivorship
Official journal of International Society for Radiation Medicine,
Immunity and Immunomodulation
ISSN pending  ·  Volume 1 (2027)

Home  /  Aims & Scope

Aims and scope.

What the journal publishes, and the scientific logic of its three sections.

Placeholder page. Final scope language to be ratified by the Publications Committee and the Editor-in-Chief.

Aims

International Journal of Radiation Medicine — Screening, Surveillance, Survivorship (IJRM-SSS) publishes rigorous, clinically consequential research spanning the full arc of radiation medicine. The journal takes as its organizing premise that ionizing radiation is an immunological as well as a cytotoxic intervention, and that its consequences must be followed from before diagnosis to decades after treatment.

Sections

Screening

  • Risk stratification models and interval selection
  • Imaging strategy, diagnostic yield, and harms of over-detection
  • Immune and molecular signatures of pre-clinical disease
  • Radiation exposure from diagnostic and screening programs

Surveillance

  • Response assessment and criteria development
  • Minimal residual disease and circulating tumor DNA
  • Longitudinal immune monitoring during and after therapy
  • Distinguishing treatment effect from recurrence

Survivorship

  • Late immune effects and persistent lymphopenia
  • Second malignancy risk and dose–response
  • Cardiovascular, pulmonary, endocrine, and cognitive sequelae
  • Patient-reported outcomes over long horizons

Cross-cutting science

Across all three sections, the journal gives priority to work on radiation-induced immunity and immunomodulation: immunogenic cell death, cGAS–STING and interferon signaling, abscopal and out-of-field response, combination with immune checkpoint inhibition and cell therapy, and immune-sparing treatment planning.

Ownership and support

IJRM-SSS is owned and published by SIRiiM, and both the Society and the journal are supported by the CureRays Institute.

Editorial authority rests with the Editor-in-Chief. Submissions authored by the Institute's founder or leadership are handled entirely externally, without exception.

Out of scope

  • Purely technical dosimetry or device engineering without a clinical or biological endpoint
  • Single-case reports without a mechanistic or methodological contribution
  • Studies with no radiation, immune, or longitudinal-outcome component

Author guidelines